These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34525293)

  • 1. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Griffith SK; Ahn GS; Wu JJ
    N Engl J Med; 2021 Sep; 385(12):1149-1150. PubMed ID: 34525293
    [No Abstract]   [Full Text] [Related]  

  • 2. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab versus Adalimumab in Plaque Psoriasis. Reply.
    Warren RB; Cioffi C; Peterson L
    N Engl J Med; 2021 Sep; 385(12):1150. PubMed ID: 34525294
    [No Abstract]   [Full Text] [Related]  

  • 4. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis.
    Zhang S; Cai L; Zhang H; Zhao Z; Liu X; Zhao Y; Zhang J
    Chin Med J (Engl); 2022 Sep; 135(18):2248-2250. PubMed ID: 35838381
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.
    Di Lernia V
    Expert Opin Biol Ther; 2017 Dec; 17(12):1553-1556. PubMed ID: 28829204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.
    van den Reek JM; Pijls PA; Tummers M; van Riel PC; Kievit W; Hoentjen F; de Jong EM
    J Am Acad Dermatol; 2016 Jan; 74(1):177-9. PubMed ID: 26702800
    [No Abstract]   [Full Text] [Related]  

  • 13. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K; Foley P; Han C; McElligott S; Muser E; Li N; Armstrong AW
    J Dermatolog Treat; 2020 Sep; 31(6):617-623. PubMed ID: 31305186
    [No Abstract]   [Full Text] [Related]  

  • 14. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
    Marcella S; Welsh B; Foley P
    Australas J Dermatol; 2011 Aug; 52(3):e8-11. PubMed ID: 21834808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of psoriasis verrucosa successfully treated with adalimumab.
    Maejima H; Katayama C; Watarai A; Nishiyama H; Katsuoka K
    J Drugs Dermatol; 2012 Nov; 11(11):e74-5. PubMed ID: 23135098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
    Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
    Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.